Comparison of Outcomes Between Rituximab and Cyclophosphamide for Primary Membranous Nephropathy: A Single Center Experience

被引：0
|
作者：
Hussain, Azm U. [1 ]
Sarween, Nadia [1 ]
机构：
[1] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
FR-PO654
引用
收藏
页码：502 / 502
页数：1
相关论文
共 50 条
  • [31] A Comparative Analysis of Efficacy of Rituximab in Patients with Primary Membranous Nephropathy
    Zhang Qianwei
    Xie Liyi
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [32] Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
    Xu, Mingyue
    Wang, Yifeng
    Wu, Meihe
    Chen, Ruiying
    Zhao, Wenqian
    Li, Mingxin
    Hao, Chuan-Ming
    Xie, Qionghong
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024,
  • [33] Hyperspectral imaging to predict the effect of cyclophosphamide in primary membranous nephropathy
    Liu, Wen
    Hou, Xiangyu
    Li, Yang
    Wang, Zunsong
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2023, 44
  • [34] Response to cyclophosphamide and rituximab therapy in idiopathic inflammatory myopathies: A single center experience
    Shahin, Amira A.
    Niazy, Marwa H.
    Haroon, Maysa M.
    EGYPTIAN RHEUMATOLOGIST, 2021, 43 (03): : 247 - 251
  • [35] Rituximab in Primary Sjogren's Syndrome: A Single Center Experience
    Logvinenko, O.
    Palshina, S.
    Vasilyev, V.
    Rodionova, E.
    Safonova, T.
    Gayduk, I.
    Sokol, E.
    SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2015, 81 (05) : 435 - 435
  • [36] Profile and primary treatment outcomes in membranous nephropathy
    Kumar, M. K. Hemanth
    Sandhu, Jashan
    Sandhu, Jasvinder S.
    SAUDI MEDICAL JOURNAL, 2022, 43 (09) : 1051 - 1056
  • [37] Outcomes of primary membranous nephropathy refractory to immunosuppressants
    Nayak, Saurabh
    Chauhan, Prabhat
    Jha, Vivekanand
    Ramachandran, Raja
    Bose, Bhadran
    CLINICAL KIDNEY JOURNAL, 2024, 17 (05)
  • [38] The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy
    Fernandez-Juarez, Gema
    Rojas-Rivera, Jorge
    van de Logt, Anne-Els
    Justino, Joana
    Sevillano, Angel
    Caravaca-Fontan, Fernando
    Avila, Ana
    Rabasco, Cristina
    Cabello, Virginia
    Varela, Alfonso
    Diez, Montserrat
    Martin-Reyes, Guillermo
    Goicoechea Diezhandino, Marian
    Quintana, Luis F.
    Agraz, Irene
    Ramon Gomez-Martino, Juan
    Cao, Mercedes
    Rodriguez-Moreno, Antolina
    Rivas, Begona
    Galeano, Cristina
    Bonet, Jose
    Romera, Ana
    Shabaka, Amir
    Plaisier, Emmanuelle
    Espinosa, Mario
    Egido, Jesus
    Segarra, Alfonso
    Lambeau, Gerard
    Ronco, Pierre
    Wetzels, Jack
    Praga, Manuel
    KIDNEY INTERNATIONAL, 2021, 99 (04) : 986 - 998
  • [39] Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up
    Zonozi, Reza
    Laliberte, Karen
    Huizenga, Noah R.
    Rosenthal, Jillian K.
    Jeyabalan, Anushya
    Collins, A. Bernard
    Cortazar, Frank B.
    Niles, John L.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 78 (06) : 793 - 803
  • [40] A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy
    Wang, Yi
    Ma, Xiaoyan
    Yang, Xinyu
    Bai, Shoujun
    Zang, Xiujuan
    Liao, Lin
    Wang, Yakun
    Lv, Zexin
    Zhang, Ting
    Zhuang, Shougang
    Liu, Na
    RENAL FAILURE, 2024, 46 (02)
12345